PMID- 28110997
OWN - NLM
STAT- MEDLINE
DCOM- 20170503
LR  - 20170907
IS  - 1097-6787 (Electronic)
IS  - 0190-9622 (Linking)
VI  - 76
IP  - 5
DP  - 2017 May
TI  - Identification of high-risk cutaneous melanoma tumors is improved when combining 
      the online American Joint Committee on Cancer Individualized Melanoma Patient
      Outcome Prediction Tool with a 31-gene expression profile-based classification.
PG  - 818-825.e3
LID - S0190-9622(16)31168-9 [pii]
LID - 10.1016/j.jaad.2016.11.051 [doi]
AB  - BACKGROUND: A significant proportion of patients with American Joint Committee on
      Cancer (AJCC)-defined early-stage cutaneous melanoma have disease recurrence and 
      die. A 31-gene expression profile (GEP) that accurately assesses metastatic risk 
      associated with primary cutaneous melanomas has been described. OBJECTIVE: We
      sought to compare accuracy of the GEP in combination with risk determined using
      the web-based AJCC Individualized Melanoma Patient Outcome Prediction Tool.
      METHODS: GEP results from 205 stage I/II cutaneous melanomas with sufficient
      clinical data for prognostication using the AJCC tool were classified as low
      (class 1) or high (class 2) risk. Two 5-year overall survival cutoffs (AJCC 79%
      and 68%), reflecting survival for patients with stage IIA or IIB disease,
      respectively, were assigned for binary AJCC risk. RESULTS: Cox univariate
      analysis revealed significant risk classification of distant metastasis-free and 
      overall survival (hazard ratio range 3.2-9.4, P < .001) for both tools. In all,
      43 (21%) cases had discordant GEP and AJCC classification (using 79% cutoff).
      Eleven of 13 (85%) deaths in that group were predicted as high risk by GEP but
      low risk by AJCC. LIMITATIONS: Specimens reflect tertiary care center referrals; 
      more effective therapies have been approved for clinical use after accrual.
      CONCLUSIONS: The GEP provides valuable prognostic information and improves
      identification of high-risk melanomas when used together with the AJCC online
      prediction tool.
CI  - Copyright (c) 2016 American Academy of Dermatology, Inc. Published by Elsevier
      Inc. All rights reserved.
FAU - Ferris, Laura K
AU  - Ferris LK
AD  - Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh,
      Pennsylvania. Electronic address: ferrlk@upmc.edu.
FAU - Farberg, Aaron S
AU  - Farberg AS
AD  - National Society for Cutaneous Medicine, New York, New York.
FAU - Middlebrook, Brooke
AU  - Middlebrook B
AD  - Castle Biosciences Inc, Friendswood, Texas.
FAU - Johnson, Clare E
AU  - Johnson CE
AD  - Castle Biosciences Inc, Friendswood, Texas.
FAU - Lassen, Natalie
AU  - Lassen N
AD  - Castle Biosciences Inc, Friendswood, Texas.
FAU - Oelschlager, Kristen M
AU  - Oelschlager KM
AD  - Castle Biosciences Inc, Friendswood, Texas.
FAU - Maetzold, Derek J
AU  - Maetzold DJ
AD  - Castle Biosciences Inc, Friendswood, Texas.
FAU - Cook, Robert W
AU  - Cook RW
AD  - Castle Biosciences Inc, Friendswood, Texas.
FAU - Rigel, Darrell S
AU  - Rigel DS
AD  - Ronald O. Perelman Department of Dermatology, New York University School of
      Medicine, New York, New York.
FAU - Gerami, Pedram
AU  - Gerami P
AD  - Department of Dermatology, Feinberg School of Medicine, Northwestern University, 
      Chicago, Illinois; Robert H. Lurie Cancer Center, Feinberg School of Medicine,
      Northwestern University, Chicago, Illinois.
LA  - eng
PT  - Journal Article
DEP - 20170119
PL  - United States
TA  - J Am Acad Dermatol
JT  - Journal of the American Academy of Dermatology
JID - 7907132
SB  - IM
CIN - J Am Acad Dermatol. 2017 May;76(5):826-828. PMID: 28411773
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Melanoma/*genetics/*secondary
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Recurrence, Local/*genetics
MH  - Neoplasm Staging
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Risk Factors
MH  - Skin Neoplasms/*genetics/*pathology
MH  - Survival Rate
MH  - *Transcriptome
MH  - Young Adult
OTO - NOTNLM
OT  - American Joint Committee on Cancer
OT  - cutaneous melanoma
OT  - gene expression profile
OT  - metastasis
OT  - prognosis
OT  - staging
EDAT- 2017/01/24 06:00
MHDA- 2017/05/04 06:00
CRDT- 2017/01/24 06:00
PHST- 2016/03/16 00:00 [received]
PHST- 2016/11/16 00:00 [revised]
PHST- 2016/11/20 00:00 [accepted]
PHST- 2017/01/24 06:00 [pubmed]
PHST- 2017/05/04 06:00 [medline]
PHST- 2017/01/24 06:00 [entrez]
AID - S0190-9622(16)31168-9 [pii]
AID - 10.1016/j.jaad.2016.11.051 [doi]
PST - ppublish
SO  - J Am Acad Dermatol. 2017 May;76(5):818-825.e3. doi: 10.1016/j.jaad.2016.11.051.
      Epub 2017 Jan 19.